

# Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?

Leif R. Erhardt

Department of Cardiology, Cardiology Research Unit, Malmö University Hospital, Malmö, Sweden

**Key words:**  
Heart failure;  
Therapy.

The finely-tuned increases and decreases in the intracellular calcium levels in myocytes ultimately regulate the contraction and relaxation of the heart. Therapeutic agents can improve or interfere with this delicate balance. Calcium sensitizers enhance cardiac contraction by improving the use of calcium that is available, rather than by inundating the cell with excessive calcium, as is the case with traditional inotropes. With the sensitizing mechanism, the energy cost of contraction is maintained at a near-normal level, and the threat of arrhythmias and sudden death is low. Levosimendan is the first calcium sensitizer to become available for the treatment of patients with acute heart failure. In recent clinical studies, levosimendan increased cardiac output and stroke volume without significantly increasing oxygen demand. By its additional action as a vasodilator (via potassium channel opening), levosimendan also corrects the hemodynamic decompensation, thus lowering the pulmonary capillary wedge pressure and systemic vascular resistance. Furthermore, levosimendan increases the coronary circulation thus leading to an improved function of the stunned myocardium and lessened ischemia. Taken together, levosimendan's primary calcium-sensitizing action, along with its complementary vasodilator properties, make this new drug a highly promising agent for the treatment of patients with acute heart failure.

(Ital Heart J 2003; 4 (Suppl 2): 27S-33S)

© 2003 CEPI Srl

Address:

Prof. Leif R. Erhardt

Department of Cardiology  
Cardiology Research Unit  
Malmö University Hospital  
205 02 Malmö  
Sweden  
E-mail:  
Leif.Erhardt@  
medforsk.mas.lu.se


## Introduction

**The role of calcium in normal cardiac contraction.** The finely-tuned increases and decreases in the intracellular calcium ( $\text{Ca}^{2+}$ ) levels in myocytes ultimately regulate contraction and relaxation of the heart. During normal systole, depolarization of the myocyte membrane induces a spike in intracellular  $\text{Ca}^{2+}$ , which in turn promotes the release of stored  $\text{Ca}^{2+}$  from within the sarcoplasmic reticulum to the cell's interior<sup>1-3</sup>. A subsequent fall in the calcium levels allows relaxation and recovery. Plasma membrane-associated  $\text{Na}^+/\text{Ca}^{2+}$  exchangers and ion channels control the movement of calcium in and out of the cell, while the sarcoplasmic reticulum regulates calcium release and uptake within the cell<sup>4</sup> (Fig. 1). The movement of intracellular ions depends on energy, which is derived from the breakdown of adenosine triphosphate (ATP) to adenosine diphosphate and phosphate ions; the synthesis of replacement ATP requires cellular oxygen consumption. In heart failure, the intracellular  $\text{Ca}^{2+}$  levels are inappropriately regulated; hence, contractility is reduced,


and the potential for arrhythmias is increased<sup>5</sup>.

Myocyte shortening or contraction is mediated by the energy-dependent sliding of actin and myosin filaments over each other. The process is regulated by a series of associated proteins including troponin C, troponins I and T and tropomyosin (Fig. 2). Intracellular  $\text{Ca}^{2+}$  binds to a specific site on troponin C. This action is central to contraction because it ultimately triggers a conformational change of tropomyosin, a downstream regulatory protein. In its altered conformation, tropomyosin allows the formation of cross-bridges between the globular myosin heads and the thin actin filaments, thus promoting filament sliding that is essential to myocyte contraction. In cardiac diastole, calcium re-uptake by the sarcoplasmic reticulum reverses these actions; tropomyosin returns to a conformation that prevents actin-myosin bridging, the actin and myosin filaments become disengaged, and myocyte relaxation ensues.

Myocardial contractility can be regulated upstream or downstream from the site



**Figure 1.** Intracellular calcium ( $Ca^{2+}$ ) handling in cardiomyocytes. Plasma membrane-associated  $Na^+/Ca^{2+}$  exchangers and ion channels control the movement of  $Ca^{2+}$  in and out of the cell. Within the cell, ryanodine receptors (RyR) and the sarcoplasmic reticulum (SR)  $Ca^{2+}$ -ATPase pump (SERCA2a) regulate the  $Ca^{2+}$  movement in and out of the SR organelle.




**Figure 2.** Mechanism of myocyte contractile proteins. A: cardiac contraction normally occurs when the globular heads of myosin molecules interact with the actin filaments to form chemical cross-bridges for sliding. During relaxation, regulatory troponins (TnC, TnT, TnI) and tropomyosin (TM) block the actin-myosin interaction so that the bridges do not form. B: calcium ( $Ca^{2+}$ )-induced changes in the troponin/TM complex. To initiate contraction, the intracellular  $Ca^{2+}$  levels increase, and troponin C binds  $Ca^{2+}$  and consequently promotes a conformational change that ultimately facilitates actin-myosin bridging. C: levosimendan stabilizes the  $Ca^{2+}$ -induced changes in the troponin/TM complex. Levosimendan acts by binding troponin C (in a  $Ca^{2+}$ -dependent manner), in turn stabilizing its conformational change and influencing its interaction with the downstream regulator TM. These changes facilitate and prolong actin-myosin cross-bridge formation, thus increasing the force of contraction.

of binding of  $Ca^{2+}$  to troponin C (Fig. 3). For example, a traditional inotrope such as dobutamine increases the release of  $Ca^{2+}$  from the sarcoplasmic reticulum – an upstream action that facilitates contraction. Alternatively, stabilization of the troponin C-tropomyosin interaction – as mediated by the new therapeutic agent levosimendan – is a downstream action that also promotes contraction. Central regulation, by enhancing the binding of  $Ca^{2+}$  to troponin C, is another possible way of increasing contractility, although agents with this mechanism are not presently available for clinical use.

**The mechanism of acute heart failure.** An episode of severe cardiac dysfunction is referred to as acute heart failure<sup>6-8</sup>. Acute heart failure may onset *de novo*, as in patients who have experienced myocardial infarction. Alternatively, patients with chronic heart disease can become acutely decompensated for reasons such as the

occurrence of fluid overload, atrial fibrillation, myocardial ischemia or infection<sup>9</sup>. In acute heart failure, the depressed myocardial contractility leads to systolic dysfunction with a resultant deficiency in tissue oxygenation. An impaired ventricular relaxation leads to diastolic dysfunction with consequent congestion of the lungs (left ventricular dysfunction) and/or congestion of the liver and kidneys (right ventricular dysfunction)<sup>9</sup>.

The loss of cardiac contractility is associated with a sustained activation of the neurohormonal systems (the renin-angiotensin-aldosterone system and the sympathetic nervous system), thus causing vasoconstriction, volume expansion and ventricular remodeling which, in turn, worsen the conditions of the failing heart<sup>10</sup>. Therefore, mechanically-driven heart failure treatments target the reduced cardiac contractility as well as the exaggerated neurohormonal responses.



**Figure 3.** Comparison of the mechanisms of action for agents that enhance contractility. In normal systole, depolarization of the myocyte membrane induces a spike in intracellular calcium ( $\text{Ca}^{2+}$ ), which in turn promotes the release of the stored  $\text{Ca}^{2+}$  from within the sarcoplasmic reticulum to the cell's interior. Binding of this released  $\text{Ca}^{2+}$  to a specific site on troponin C (TnC) ultimately triggers a conformational change of tropomyosin (TM), a downstream regulatory protein. In its altered conformation, TM allows the formation of cross-bridges between the globular myosin heads and the thin actin filaments, thus promoting the filament sliding that is essential to sarcomere shortening and myocyte contraction. cAMP = cyclic adenosine monophosphate.

### Traditional strategies for the treatment of acute heart failure.

When a patient with acute heart failure arrives at the emergency department, the earliest therapy is generally directed towards treating the symptoms – edema, angina, and acute dyspnea. Positive airway pressure is usually given immediately to improve oxygen supply. Diuretics are essential to reduce fluid overload, and vasodilators (mainly nitrates) are used to reduce the filling pressures and thereby relieve dyspnea and angina<sup>7</sup>.

Drugs that increase contraction (positive inotropes) have been used as the next level of therapy for patients with systolic dysfunction. Unfortunately, traditional inotropes (beta-agonists and phosphodiesterase inhibitors) are now recognized as having the serious drawback of decreasing the long-term survival<sup>11,12</sup>. These inotropes act through the common mechanism of raising the levels of cyclic adenosine monophosphate (cAMP) in cardiac myocytes. In turn, the elevated cAMP levels promote the release of calcium from the sarcoplasmic reticulum for a consequent rise in cytosolic  $\text{Ca}^{2+}$  – an action that ultimately generates the contractile force (Fig. 3). Beta-agonists such as dobutamine increase cAMP production, while phosphodiesterase inhibitors such as milrinone prevent cAMP breakdown. It is now understood that such therapeutic agents increase the risk of death because a sustained elevation of intracellular  $\text{Ca}^{2+}$  increases oxygen demand, impairs relaxation, and exacerbates ischemia and arrhythmias<sup>11,13</sup>.

Altogether, the adverse outcomes with traditional inotropes clearly call for an alternative strategy for the treatment of patients with acute heart failure. When acute heart failure occurs, it is important to consider the long-term outcomes as well as the short-term contractile and hemodynamic needs.

### Calcium sensitization: rational therapy to increase cardiac contractility

Calcium sensitizers work by improving the use of  $\text{Ca}^{2+}$  that is available in the cell, rather than by inundating the cell with excessive  $\text{Ca}^{2+}$ . Consequently, the energy cost of contraction is maintained at a near-normal level, thus lowering the threat of arrhythmias and sudden death<sup>1</sup>. Although a number of drugs can now be categorized as calcium sensitizers, levosimendan has evolved as one of the more promising representatives of this group<sup>14</sup>. In fact, levosimendan is about 100 times more potent as a calcium sensitizer than pimobendan and other agents, and it also appears to provide long-term survival advantages<sup>9,15</sup>.

### Levosimendan is a safe and effective calcium sensitizer.

Levosimendan selectively binds to cardiac troponin C that is  $\text{Ca}^{2+}$ -saturated as a result of the normal calcium transient<sup>16-20</sup>. Such binding stabilizes and prolongs a specific conformation of troponin C that ultimately mediates myofibril contraction. Through a cascade of changes in troponins I and T and in tropomyosin, bridges between the actin and myosin filaments form, thus producing force-generation with a prolonged contraction (Fig. 2C). Calcium-sensitizing actions of levosimendan have been evidenced by studies in the skinned fiber from cardiac tissue<sup>21</sup>, in intact cardiomyocytes and in muscle strips<sup>22-24</sup>. Consistent with this mechanism, clinical studies have provided substantial support for levosimendan's ability to significantly increase cardiac output and stroke volume<sup>25-28</sup>.

While levosimendan improves contractility, it does not impair relaxation<sup>15,29</sup>. Levosimendan binds optimally to


troponin C at normal calcium peak levels, but dissociates from this protein during the decay of the intracellular  $Ca^{2+}$  transient preceding the relaxation phase<sup>9,29</sup>.

Myocyte traces can be used to measure contraction (percentage of cell shortening) and the amount of released  $Ca^{2+}$  to promote the contraction ( $[Ca^{2+}]_i$  transient expressed as indo-1 fluorescence ratio), as illustrated in figure 4<sup>22</sup>. While levosimendan generates a contractile trace with an amplitude similar to that of the traditional inotropes dobutamine and milrinone (Fig. 4, upper), these latter agents elicit a substantially higher level of calcium to achieve this contraction (Fig. 4, lower). Following contraction, the elevated intracellular  $Ca^{2+}$  levels fall off normally with the calcium sensitizer levosimendan, but are sustained longer with the traditional inotropes, thus impairing relaxation. With levosimendan, the intracellular  $Ca^{2+}$  levels do not rise above normal, and the sarcoplasmic reticulum is unlikely to get overloaded with  $Ca^{2+}$ ; hence, arrhythmias due to inappropriate  $Ca^{2+}$  dumping are also unlikely. In fact, electrocardiographic recordings of the effects of intravenous levosimendan on patients with severe heart failure showed no evidence of a life-threatening proarrhythmic potential<sup>30</sup>. In another study, dynamic positron emission tomography with  $[^{11}C]$ acetate was used to assess myocardial oxygen consumption in patients hospitalized with heart failure and treated with levosimendan<sup>31</sup>. The results showed that levosimendan enhanced cardiac output without oxygen wasting, particularly by improving the efficiency in the right ventricle<sup>31</sup>.


**Beyond calcium sensitization: additional benefits of levosimendan.** In another cellular action, levosimendan promotes vasodilation by opening the ATP-sensitive potassium channels<sup>32,33</sup>. The resultant venous and arteriolar dilation reduces cardiac preload and afterload, improves oxygen supply to the myocardium (Fig. 5), and enhances the renal blood flow<sup>32,34-37</sup>. Such vasodilation by levosimendan is also thought to underlie the reduc-

tions in infarct size and myocardial ischemia (Fig. 6), as well as to afford anti-stunning benefits (Fig. 7)<sup>38-41</sup>.


In recent clinical studies, the dual-mechanism levosimendan increased cardiac output and stroke volume, while concomitantly decreasing the pulmonary capillary wedge pressure and systemic vascular resistance<sup>25-28</sup>. Importantly, the symptoms of dyspnea and fatigue were significantly lessened in levosimendan-treated patients<sup>26</sup>. Furthermore, due to its unique sensitizing mechanism and low-energy cost to the heart, levosimendan appeared to provide long-term survival benefits for patients who experienced acute heart failure after myocardial infarction as well as for those who were hospitalized with acutely decompensated chronic heart failure<sup>27,28</sup>.




**Figure 4.** Typical myocyte traces showing the percentage of cell shortening (a measure of contraction) and the  $[Ca^{2+}]_i$  transient expressed as the indo-1 fluorescence ratio (a measure of the  $Ca^{2+}$  released to promote contraction). While levosimendan elicits a contraction with an amplitude similar to that generated by a traditional inotrope such as dobutamine (upper), the latter necessitates a substantially higher level of calcium to achieve this contraction (lower). Following contraction, the elevated intracellular  $Ca^{2+}$  levels fall off normally with the calcium sensitizer levosimendan (dotted arrows), but are sustained longer with the traditional inotrope, thus impairing relaxation (black arrows). Adapted from Lancaster and Cook<sup>22</sup>.



**Figure 5.** Levosimendan tends to increase coronary blood flow. For this study, 23 low-risk patients undergoing coronary artery bypass graft surgery were enrolled. Patients were randomized to receive placebo or levosimendan at the indicated doses as a 5-min infusion. The average increase in coronary blood flow was 35 ml/min, with a *p* value of 0.0539 when both levosimendan doses were combined in the analysis. Adapted from Lilleberg et al.<sup>34</sup>.



**Figure 6.** Anti-ischemic effect of levosimendan: a canine in vivo model. The myocardial infarct was mediated by 60-min occlusion of the left anterior descending coronary artery; the extent of the infarct was measured 1 hour after the injury and 3 hours after placebo or levosimendan infusion. With levosimendan, the myocardial infarct size decreased from 24 to 11%. Adapted from Kersten et al.<sup>40</sup>.



**Figure 7.** Anti-stunning effect of levosimendan in a canine model. Myocardial stunning was elicited in anesthetized dogs by five 5-min occlusions of the left anterior descending coronary artery (interspersed with reperfusion). Three hours after the final treatment, levosimendan was administered via an intracoronary catheter; increasing doses were sequentially given for 10 min at each dose. The regional contractile function was measured using a pair of implanted segment length transducers. The percentage segment shortening was markedly decreased in the post-occlusion animals, consistent with myocardial stunning. The recovery with levosimendan treatment was dose-dependent. Adapted from Jamali et al.<sup>41</sup>.

**Practical use of levosimendan today.** Levosimendan is indicated for the short-term treatment of acutely decompensated severe chronic heart failure<sup>42</sup>. Levosimendan is administered in hospitalized patients by peripheral- or central-intravenous infusion<sup>43</sup>. Treatment is usually initiated as a loading dose (12 to 24 µg/kg infused over 10 min) followed by a continuous infusion (0.1 µg/kg/min) up to 24 hours.

There are as yet no definitive data regarding the benefits of intermittent levosimendan infusions, but with the hemodynamic effects of 24-hour infusions lasting up to 1 week, levosimendan may prove an ideal agent for pulsed intravenous therapy, particularly in patients with poor symptom control<sup>44</sup>.

### Future clinical uses for calcium sensitization by levosimendan

Although levosimendan's full clinical utility continues to evolve, there appears to be considerable potential for its use beyond the treatment of acutely decompensated chronic heart failure. Levosimendan is also expected to be effective for the treatment of patients with acute post-infarction heart failure<sup>28</sup>, for patients with diastolic heart failure<sup>44</sup>, for those with a low cardiac output following coronary artery bypass grafting<sup>34,35</sup> and for circulatory failure due to septic shock<sup>46</sup>. In addition, levosimendan has the potential for supporting cardiac function during the start-up of beta-blocker therapy, for weaning patients from cardiopulmonary bypass, for individuals with valvular abnormalities and for those with myocarditis.

### Summary

Calcium sensitizers enhance cardiac contraction by improving the use of the Ca<sup>2+</sup> that is normally available. With this mechanism, the energy cost of contraction is maintained at a near-normal level, and the threat of arrhythmias and sudden death is low. Levosimendan is the first calcium sensitizer to become available for the treatment of patients with acute heart failure. In recent clinical studies, levosimendan increased cardiac output and stroke volume without significantly increasing oxygen demand. The vasodilator properties of levosimendan (via potassium-channel opening) also contribute to the correction of the hemodynamic decompensation by lowering the pulmonary capillary wedge pressure and systemic vascular resistance. Furthermore, levosimendan increases the coronary circulation leading to an improved function of the stunned myocardium and lessened ischemia. Taken together, levosimendan's primary calcium-sensitizing action, along with its complementary vasodilator properties, make this new drug a highly promising agent for the treatment of patients with acute heart failure (Table I).

**Table I.** Summary of the clinical benefits of levosimendan.

Calcium-sensitizing effects
Enhanced cardiac output
Increased stroke volume
No significant increase in oxygen demand
Potassium-channel opening (vasodilator) effects
Reduction in preload and afterload
Increased coronary blood flow
Anti-ischemic effect
Anti-stunning effect

## Acknowledgments

The author thanks Cecilia Hofmann, PhD, for her technical and editorial assistance in the preparation of this manuscript.

## References

1. Arteaga GM, Kobayashi T, Solaro RJ. Molecular actions of drugs that sensitize cardiac myofilaments to  $Ca^{2+}$ . *Ann Med* 2002; 34: 248-58.
2. Endoh M. Mechanisms of action of novel cardiotoxic agents. *J Cardiovasc Pharmacol* 2002; 40: 323-38.
3. Nielsen-Kudski J, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? *J Cardiovasc Pharmacol* 1995; 26 (Suppl 1): S77-S84.
4. Bers D. Calcium fluxes involved in control of cardiac myocyte contraction. *Circ Res* 2000; 87: 275-81.
5. Pogwizd S, Schlotthauer K, Li L, et al. Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. *Circ Res* 2001; 88: 1159-67.
6. Poole-Wilson PA. Treatment of acute heart failure: out with the old, in with the new. *JAMA* 2002; 287: 1578-80.
7. Remme W, Swedberg K, on behalf of the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. *Eur Heart J* 2001; 22: 1527-60.
8. Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. *Prog Cardiovasc Dis* 1998; 41: 207-24.
9. Mebazaa A, Erhardt L. Levosimendan: a new dual-action drug for treatment of acute heart failure. *Int J Clin Pract* 2003, in press.
10. Chin B, Yip G. New pharmacological strategies for treatment of heart failure. *Curr Opin Invest Drugs* 2001; 2: 923-8.
11. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. *Am Heart J* 2001; 142: 393-401.
12. Taneja T, Johnson MR, Gheorghide M. Intravenous therapy for chronic heart failure exacerbations. *Congest Heart Fail* 1999; 5: 199-207.
13. Cuffe MS, Califf RM, Adams KF Jr, et al, for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. *JAMA* 2002; 287: 1541-7.
14. Leier CV. Therapeutic approaches and the role of calcium-sensitizing agents in end-stage congestive heart failure. *Am J Cardiol* 1999; 83 (Suppl 12B): I26-I28.
15. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. *J Cardiovasc Pharmacol* 1995; 26 (Suppl 1): S10-S19.
16. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. *J Mol Cell Cardiol* 1995; 27: 1859-66.
17. Levijoki J, Pollesello P, Kaheinen P, Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. *Eur J Pharmacol* 2001; 419: 243-8.
18. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new calcium sensitizer, levosimendan, to recombinant cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. *J Biol Chem* 1994; 269: 28584-90.
19. Sorsa T, Heikkinen S, Abbott M, Abusamjadme E, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. *J Biol Chem* 2001; 276: 9337-43.
20. Endoh M. Mechanism of action of  $Ca^{2+}$  sensitizers - update 2001. *Cardiovasc Drugs Ther* 2001; 15: 397-403.
21. Edes I, Kiss E, Kitada Y, et al. Effects of levosimendan, a cardiotoxic agent targeted to troponin C, on cardiac function and on phosphorylation and  $Ca^{2+}$  sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. *Circ Res* 1995; 77: 107-13.
22. Lancaster M, Cook S. The effects of levosimendan on  $[Ca^{2+}]_i$  in guinea-pig isolated ventricular myocytes. *Eur J Pharmacol* 1997; 339: 97-100.
23. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. *Circulation* 1998; 98: 2141-7.
24. Janssen PM, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. *Eur J Pharmacol* 2000; 404: 191-9.
25. Nieminen M, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. *J Am Coll Cardiol* 2000; 36: 1903-12.
26. Slawsky MT, Colucci WS, Gottlieb SS. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. *Circulation* 2000; 102: 2222-7.
27. Follath F, Cleland JG, Just H, et al, for the Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output failure (the LIDO study): a randomised double-blind trial. *Lancet* 2002; 360: 196-202.
28. Moiseyev V, Poder P, Andrejevs N, et al, for the RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). *Eur Heart J* 2002; 23: 1422-32.
29. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. *J Cardiovasc Pharmacol* 1995; 25: 794-801.
30. Singh BN, Lilleberg J, Sandell EP, et al. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. *Am J Cardiol* 1999; 83 (Suppl 12B): I16-I20.
31. Ukkonen H, Saraste M, Akkila J, Knuti J. Myocardial efficiency during levosimendan infusion in congestive heart failure. *Clin Pharmacol Ther* 2000; 68: 522-31.
32. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. *J Cardiovasc Pharmacol* 2001; 37: 367-74.
33. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel  $Ca^{2+}$  sensitizer, activates the glibenclamide-sensitive  $K^+$  channel in rat arterial myocytes. *Eur J Pharmacol* 1997; 333: 249-59.
34. Lilleberg J, Nieminen M, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilisation early after coronary artery bypass grafting. *Eur Heart J* 1998; 19: 660-8.
35. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. *J Pharmacol Exp Ther* 1999; 288: 316-25.

36. Pataricza J, Hohn J, Petri A, Balogh A, Papp J. Comparison of the vasorelaxing effect of cromakalim and the new inodilator levosimendan in human isolated portal vein. *J Pharm Pharmacol* 2000; 52: 213-7.
37. Pagel P, Hettrick D, Warltier D. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. *Br J Pharmacol* 1996; 119: 609-15.
38. DuToit E, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligations and reperfusion in the in vivo pig model. *Heart* 2001; 86: 81-7.
39. DuToit E, Muller C, McCarthy J, Opie L. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. *J Pharmacol Exp Ther* 1999; 290: 505-14.
40. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. *Anesth Analg* 2000; 90: 5-11.
41. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. *Anesth Analg* 1997; 85: 23-9.
42. Levosimendan concentrate for solution for infusion. *International Medical Data Sheet* 2002; Abbott (on file).
43. Orion Corp. SIMDAX Summary of Product Characteristics, 2001.
44. Cleland J. Levosimendan: a new era for inodilator therapy for heart failure? *Curr Opin Cardiol* 2002; 17: 257-65.
45. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. *J Cardiovasc Pharmacol* 1999; 34: 219-28.
46. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. *Crit Care Med* 2001; 29: 2185-93.